Use of pro-apoptotic factors in treatment of atherosclerosis

Details Use of pro-apoptotic factors in treatment of atherosclerosis Use of pro-apoptotic factors in treatment of atherosclerosis

2007-11-20

2007-11-20

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093200

Reexamination Certificate

active

10461200

ABSTRACT:
The present invention features a novel method of treating vascular disease that involves modifying smooth muscle cells to express a gene encoding a protein having both anti-inflammatory and pro-apoptotic activity. Preferably, the protein of the invention also has an anti-proliferative effect in smooth muscle cells. In general, the method is useful in preparing vascularized organs and vessels for transplant into a patient. Alternatively, the present invention can be applied to treat atherosclerotic lesions in damaged vessels.

REFERENCES:
patent: 5459251 (1995-10-01), Tsujimoto et al.
patent: 5571523 (1996-11-01), Lee et al.
patent: 5776905 (1998-07-01), Gibbons et al.
patent: 6043055 (2000-03-01), Hsueh et al.
patent: 0 670 369 (1995-09-01), None
patent: WO 90/06997 (1990-06-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/18794 (1993-09-01), None
patent: WO 94/10305 (1994-05-01), None
patent: WO 94/27426 (1994-12-01), None
patent: WO 95/00642 (1995-01-01), None
patent: WO 95/15084 (1995-06-01), None
patent: WO 97/30083 (1997-08-01), None
Ferran et al (Transplantation Proceedings 29: 879-880, 1997).
VanBuskirk et al (Transplant Immunology 278(22): 1993-1999, 1997).
Verma et al (Nature 389: 239-242, 1997).
Anderson (Nature 392:25-30, 1998).
Romano et al (Stem Cells 18: 19-39, 2000).
Somia and Verma (Nature Reviews Genetics 1: 91-99, 2000).
Rudinger (In Peptide Hormones J.A. Parsons, Ed. University Park Press, Baltimore, 1976, pp. 1, 6, and 7).
Ngo et al (In The Protein Folding Problem and Tertiary Structure Prediction, K. Merz Jr. and S. Legrand, Eds. Birkhauser, Boston, 1994, pp. 433 and 492-495.).
Miller et al. (FASEB J. 9: 190-199, 1995).
Deonarain (Exp. Opin. Ther. Patents 8(1):53-69, 1998).
Crystal (Science 270: 404-410, 1995).
Pouton et al (Adv. Drug Del. Rev. 46: 187-203, 2001).
Read et al (Adv. Gen. 53:19-46, 2005).
Guo et al (Proc. Nat. Acad. Sci. USA 101(25):9205-9210, 2004).
Anderson, “Human gene therapy,”Nature392:25-30 (1998).
Arvelo et al., “A novel function for A20 in smooth muscle cells: Inhibition of activation and proliferation. A means of protection from transplant-associated arteriosclerosis,”Transplant 98 Book of Abstracts(Abstract) (1998).
Arvelo et al., “Combined expression of A20 in endothelial and smooth muscle cells serve an anti-inflammatory and anti-transplant arteriosclerosis potential: A means of achieving long-term xenograft survival,”The 5thCongress of the International Xenotransplantation Association(Abstract) (1999).
Bach et al., “Accommodation of Vascularized Xenografts: Expression of “Protective Genes” by Donor Endothelial Cells in a Host Th2 Cytokine Environment,”Nature Medicine3:196-204 (1997).
Bach et al., “A20 gene therapy for transplantation and inflammatory conditions and means therefor,” U.S. Appl. No. 09/576,464, filed May 23, 2000.
Bach et al., “Protective genes expressed in endothelial cells: a regulatory response to injury,”Immunology Today18:483-486 (1997).
Bach et al., “Delayed Xenograft Rejection,”Immunology Today17:379-383 (1996).
Bach et al., “Endothelial cell activation and thromboregulation during xenograft rejection,”Immunological Reviews141:5-30 (1994).
Badrichani et al., “Bcl-2 and Bcl-Xl Serve an Anti-Inflammatory Function in Endothelial Cells Through Inhibition of NF-kB,”The Journal of Clinical Investigation103:543-553 (1999).
Baldwin et al., “The NF-kB and IkB Proteins: New Discoveries and Insights,”Ann. Rev. Immunol.14:649-681 (1996).
Barinaga, “Life-death balance within the cell,”Science274:724 (1996).
Beg et al., “An essential role for NF-κB in preventing TNF-α-Induced cell death,”Science274:782-784 (1996).
Bellas et al., “Expression of a constitutive NF-kB-like activity is Essential for Proliferation of Cultured Bovine Vascular Smooth Muscle Cells,”J. Clin. Invest.96:2521-2527 (1995).
Björkerud et al., “Contrary Effects of Lightly and Strongly Oxidized LDL with Potent Promotion of Growth Verses Apoptosis on Arterial Smooth Muscle Cells, Moacrophages, and Fibroblasts,”Arterioscler. Thromb. Vasc. Biol.16:415-424 (1996).
Boise et al., “Bcl-x, bcl-2-related gene that functions as a dominant regulator of apoptotic cell death,”Cell74:597-608 (1993).
Bourcier et al., “The Nuclear Factor k-B Signaling Pathway Participates in Dysregulation of Vascular Smooth Muscle Cells in vitro and in Human Atherosclerosis,”J. Biol. Chem.272:15817-15824 (1997).
Brand et al., “Activated Transcription Factor Nuclear Factor-Kappa B is Present in the Atherosclerotic Lesion,”J. Clin. Invest.97:1715-1722 (1996).
Bustos and Platt, “Platlet-Endothelial Cell Interaction in a Xenograft Model,”Transplantation Proceedings29: 886 (1997).
Carrington et al., “Novel Responses to Transgenic Pig Endothelial Cells to Stimulation by Human Cytokines in Terms of H-Daf, E-Selectin and Major Histocompatibility Complex Class II Expression,”Transplantation Proceedings29: 887 (1997).
Choi et al., “The role of bcl-xLin CD40-mediated rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells,”Eur. J. Immunology25:1352-1357 (1995).
Clay et al., “Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer,”Pathology Oncology Research5:3-15 (1999).
Clemens et al., “Molecular basis for specific recognition of both RNA and DNA by a zinc finger protein,”Science260:530-533 (1993).
Collins, “Biology of disease. Endothelial nuclear factor-κB and the initiation of the atherosclerotic lesion,”Laboratory Investigation68(5):499-508 (1993).
Cooper et al., “A20 blocks endothelial cell activation through a NF-κB-dependent mechanism,”The Journal of Biological Chemistry271(30):18068-18073 (1996).
Cooper et al., “A20 Expression Inhibits Endothelial Activation,”Transplantation Proceedings29: 881 (1997).
Craig, “The BCL-2 gene family,”Seminars in Cancer Research6:35-43 (1995).
Crook et al., “An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif,”Journal of Virology67:2168-2174 (1993).
Crystal, “Transfer of genes to humans: early lessons and obstacles to success,”Science270:404-410 (1995).
de Martin et al., “Cytokine-inducible expression in endothelial cells of an lκBα-like gene is regulated by NfκB,”The EMBO Journal12(7):2773-2779 (1993).
Dixit et al., “Tumor nacrosis factor-α induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin,”J. Biol. Chem.265:2973-2978 (1990).
Dixit et al., “The antimitogenic action of tumor necrosis factor is associated with increased ap-1/c-jun proto-ocogene transcription,”J. Biol. Chem.264:16905-16909 (1990).
Evans et al., “Zinc Fingers: Gilt by association,”Cell52:1-3 (1988).
Ferran et al., “Inhibition of NF-kB by Pyrrolidine Dithiocarbamate Blocks Endothelial Cell Activation,”Biochemical and Biophysical Research Communication214:212-223 (1995).
Ferran et al., “A20 inhibits NF-κB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis,”Blood91:2249-2258 (1998).
Ferran et al., “Adenovirus-mediated gene transfer of A20 renders endothelial cells resistant to activation: a means of evaluating the role of endothelial cell activation in xenograft rejection,”Transplantation Proceedings29:879-880 (1997).
Fox et al., “Antisense Inhibition of Basic fibroblast growth factor induces apoptosis in vascular snooth muscle cells,”J. Biol. Chem.271:12578-12584 (1996).
Fryer et al., “Inhibition of Human Serum Mediated Lysis of Porcine Endothelial Cells Using a Novel Peptide Which Blocks C1Q Binding to Xenoantibody,”Transplant

Affiliated with

Also associated with

Rating

Use of pro-apoptotic factors in treatment of atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of pro-apoptotic factors in treatment of atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of pro-apoptotic factors in treatment of atherosclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3884383